Data on Biogen Hemophilia Candidates - Analyst Blog

By
A A A

Biogen Idec ( BIIB ) and partner, Swedish Orphan Biovitrum recently presented encouraging data on their hemophilia candidates, rFVIIIFc and rFIXFc. Results, which were presented at the annual meeting of the European Association for Haemophilia and Allied Disorders (EAHAD), showed that the candidates provided long-lasting protection from bleeding with fewer injections compared to the current standard of care for hemophilia patients.

The pharmacokinetic activity of rFVIIIFc (hemophilia A) and rFIXFc (hemophilia B) was compared to that of currently available treatments. Results showed that rFVIIIFc and rFIXFc stayed active in the body for a longer period of time thereby allowing the prevention of bleeding with fewer injections than currently required.

Biogen recently submitted a Biologics License Application (BLA) seeking US Food and Drug Administration (FDA) approval for rFIXFc for hemophilia B. Currently available treatments for hemophilia B include Pfizer's ( PFE ) BeneFIX.

Meanwhile, the US regulatory filing for rFVIIIFc for hemophilia A should also take place in the first half of 2013. A convenient dosing schedule (supported by a longer duration of action and a suitable safety profile) could help rFIXFc and rFVIIIFc capture share from existing products in the hemophilia market.

Upcoming Catalysts

Meanwhile, Biogen has some other significant pipeline catalysts coming up, the most important being an update on the regulatory status of Tecfidera (BG-12). Tecfidera , Biogen's oral multiple sclerosis candidate, is currently under review in both the US and the EU. A response in the US should be out by March. We believe Tecfidera could become a leader in the oral multiple sclerosis market once launched.

Biogen currently carries a Zacks Rank #3 (Hold). Biotech companies that currently look interesting include Alkermes ( ALKS ), which carries a Zacks #1 Rank (Strong Buy), and Elan ( ELN ), which carries a Zacks Rank #2 (Buy).



ALKERMES INC (ALKS): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

ELAN CP PLC ADR (ELN): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALKS , BIIB , ELN , PFE

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

106,679,460
  • $17.03 ▲ 0.47%
101,357,777
  • $38.65 ▼ 5.57%
61,830,117
  • $89.89 ▼ 4.26%
54,116,071
  • $5.11 ▼ 4.49%
50,121,934
  • $101.06 ▲ 0.10%
49,993,927
  • $3.52 ▼ 1.40%
47,717,687
  • $11.44 ▼ 4.67%
44,793,169
  • $99.05 ▼ 0.93%
As of 9/22/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com